drf-2725 has been researched along with Atherosclerosis* in 2 studies
2 review(s) available for drf-2725 and Atherosclerosis
| Article | Year |
|---|---|
[Advances in the study of anti-atherosclerosis drugs].
Several new drug targets of anti-atherosclerosis, emerging in the recent years, such as PPAR agonists, cholesteryl ester transfer protein (CETP) inhibitors, infusion of apolipoprotein A-I (apoA-I), liver X receptor (LXR) activators and phospholipid transfer protein (PLTP) inhibitors etc were reviewed. Topics: Apolipoprotein A-I; Atherosclerosis; Benzoates; Benzylamines; Cholesterol Ester Transfer Proteins; DNA-Binding Proteins; Humans; Liver X Receptors; Molecular Structure; Orphan Nuclear Receptors; Oxazines; Peroxisome Proliferator-Activated Receptors; Phenylpropionates; Quinolines; Receptors, Cytoplasmic and Nuclear | 2007 |
[Peroxisome proliferator-activated receptor alpha, gamma and the dual agonists and atherosclerosis].
Topics: Animals; Atherosclerosis; Humans; Oxazines; Phenylpropionates; PPAR alpha; PPAR gamma | 2007 |